

Multicenter Evaluation of the Etest and Disk Diffusion Methods for Differentiating Daptomycin-Susceptible from Non-Daptomycin-Susceptible *Staphylococcus aureus* Isolates

Laura A. Jevitt,¹ Grace M. Thorne,² Maria M. Traczewski,³ Ronald N. Jones,⁴
 John E. McGowan, Jr.,⁵ Fred C. Tenover,^{1*} and Steven D. Brown³

Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia 30333¹;
 Cubist Pharmaceuticals, Lexington, Massachusetts 02421²; Clinical Microbiology Institute, Wilsonville,
 Oregon 97070³; JMI Laboratories, Inc., North Liberty, Iowa 52317⁴; and Rollins School of
 Public Health, Emory University, Atlanta, Georgia 30322⁵

Received 28 March 2006/Returned for modification 3 May 2006/Accepted 26 June 2006

Daptomycin is a novel cyclic lipopeptide that is approved by the U.S. Food and Drug Administration for the treatment of complicated skin and skin structure infections associated with *Staphylococcus aureus* and other gram-positive pathogens and also staphylococcal bacteremia, including right-sided endocarditis. The Clinical and Laboratory Standards Institute (CLSI) established “susceptible-only” interpretive criteria for broth microdilution (BMD) and disk diffusion (DD) testing of daptomycin in 2005. However, a series of *S. aureus* isolates have been recovered with daptomycin MICs in the nonsusceptible range (i.e., MICs of >1 µg/ml). The objective of this study was to determine the ability of the Etest and DD methods to differentiate daptomycin-susceptible from nonsusceptible isolates of *S. aureus* compared to the results of the CLSI BMD reference method. There was a good correlation between Etest MIC results and the results of BMD among laboratories ($r = 0.86$ to 0.88), with 95.3% of the Etest MICs within a ± 1 log₂ dilution of the BMD MIC result. A total of 92 of 102 (90.2%) non-daptomycin-susceptible isolates of *S. aureus* identified by BMD in two participating laboratories were also classified as nonsusceptible by Etest. However, the very major and major error rates reported by one of the participating laboratories were 13.5 and 4.0%, respectively, primarily due to the absence of an intermediate category. The DD method, however, did not reliably differentiate daptomycin-susceptible from non-daptomycin-susceptible isolates. In 2005, daptomycin disks were voluntarily removed from the market by Cubist Pharmaceuticals. The disk diffusion breakpoints were subsequently removed from the CLSI M100 standard in 2006.

Methicillin-resistant *Staphylococcus aureus* (MRSA) infections have become increasingly challenging for clinicians to treat since these isolates are often resistant to multiple antimicrobial agents, including, in limited cases, vancomycin (3, 7, 10, 35). In recent years, several new antimicrobial agents, including linezolid, quinupristin-dalfopristin, and daptomycin (6, 8, 31, 33), have been marketed for treating serious gram-positive infections. Daptomycin is a novel, cyclic lipopeptide antimicrobial agent that is approved by the U.S. Food and Drug Administration (FDA) for the treatment of complicated skin and skin structure infections associated with *S. aureus*, including MRSA, and other gram-positive pathogens (1, 20, 33), and bacteremia, including right-sided endocarditis, for both methicillin-susceptible and methicillin-resistant *S. aureus*. The activity of daptomycin against a variety of gram-positive pathogens has been documented over several years in a number of large surveillance studies conducted in North America, Europe, and the Far East (2, 9, 15, 18, 26, 34, 36).

The concentration-dependent bactericidal activity of daptomycin requires physiological levels of free calcium ions (50 µg/ml) (28, 33). Similar levels of calcium also are required

to achieve accurate in vitro antimicrobial susceptibility testing results (2, 12, 30). This poses a challenge for in vitro agar-based susceptibility tests, since commercially available Mueller-Hinton agar plates used for disk diffusion tests vary in calcium concentration among manufacturers and from lot to lot of media (2, 12, 32). The Clinical and Laboratory Standards Institute (CLSI) sets cation standards for Mueller-Hinton broth but does not set standards for Mueller-Hinton agar. Early studies with daptomycin Etest strips (AB Biodisk, Solna, Sweden) by Fuchs et al. documented the pronounced effect of various calcium concentrations on MIC results (13). However, the results in that study indicated that Mueller-Hinton agar containing >20 µg of calcium/ml generally yielded Etest MIC results within 1 log₂ dilution of the MICs obtained using the broth microdilution method. Subsequently, dual-component daptomycin Etest strips were developed that incorporate a constant and optimal level of Ca²⁺ within the daptomycin gradient enabling the use of standard Mueller-Hinton agar plates (Etest daptomycin package insert; AB Biodisk, Solna, Sweden). Studies comparing the MIC results between the revised Etest method and the results of broth microdilution testing for enterococci and staphylococci have been reported recently (17, 19; A. A. Bolmstrom, A. Engelhardt, A. Karlsson, P. Ho, K. Mills, A. Wanger, and R. Howe, Abstr. 105th Gen. Meet. Am. Soc. Microbiol. 2005, abstr. C317, 2005; L. M. Koeth and J. M. Difranco, Abstr. 45th Intersci. Conf. Antimi-

* Corresponding author. Mailing address: Division of Healthcare Quality Promotion (G-08), Centers for Disease Control and Prevention, 1600 Clifton Rd., NE, Atlanta, GA 30333. Phone: (404) 639-3375. Fax: (404) 639-1381. E-mail: fnt1@cdc.gov.

cro. Agents Chemother., abstr. D-1641, 2005). The Etest MIC results from these studies were comparable for staphylococci and enterococci, with most results being within 1 log₂ dilution of the broth microdilution MICs.

Recently, there have been reports of daptomycin treatment failure among several patients with MRSA or enterococcal infections who were treated with prolonged courses of daptomycin (14, 21, 22, 27). A report by Hayden et al. (14) noted that the zones of inhibition for two MRSA isolates around daptomycin disks remained in the susceptible range (17 to 24 mm; susceptible breakpoint, ≥16 mm) even though the daptomycin MICs for the posttreatment isolates were nonsusceptible (4 µg/ml; susceptible breakpoint, ≤1 µg/ml). These investigators (14) and Sabol et al. (27) expressed concern that the disk diffusion method may not detect non-daptomycin-susceptible strains of staphylococci and enterococci, respectively. On the other hand, a report by Mangili et al. (21) of another daptomycin treatment failure notes that the previously daptomycin-susceptible isolates of MRSA recovered from positive blood cultures after daptomycin therapy yielded nonsusceptible results by both disk diffusion (daptomycin zone diameter = 14 mm) and broth microdilution (MIC = 2 µg/ml). That report indicated that at least some non-daptomycin-susceptible isolates are detected by the disk diffusion method.

Previous studies on the activity of daptomycin against multi-drug-resistant isolates of staphylococci and enterococci included a series of isolates for which the daptomycin MICs were in the nonsusceptible range (16). This, in conjunction with the reports noted above, prompted us to study the ability of the disk diffusion and Etest susceptibility testing methods to detect isolates for which the daptomycin MICs were in the nonsusceptible range when tested by the broth microdilution reference method. We describe here a multicenter study focused on assessing the reproducibility of daptomycin MICs when tested with multiple lots of Mueller-Hinton broth and the ability of the Etest and disk diffusion testing methods to differentiate daptomycin-susceptible from non-daptomycin-susceptible isolates of *S. aureus* using multiple lots of Mueller-Hinton agar. Although non-daptomycin-susceptible isolates of enterococci and coagulase-negative staphylococci also have been described (16), relatively few such isolates were available to us at the time of the present study. Thus, we focused our attention on *S. aureus* isolates.

MATERIALS AND METHODS

Antimicrobial agents. The daptomycin powder (lot 850753A) used for the present study was provided by Cubist Pharmaceuticals (Lexington, MA). The drug was dissolved and diluted in sterile water. A working stock solution of 1:10 was made by using cation-adjusted Mueller-Hinton broth (CA-MHB). Vancomycin was purchased from Sigma-Aldrich (St. Louis, MO). Sterile water was used as both the diluent and the solvent according to CLSI guidelines (4).

Isolate selection. A total of 150 nonduplicate clinical isolates of *S. aureus* were selected for use in the present study. Thirty-two of the isolates demonstrated either elevated daptomycin MICs (≥2 µg/ml; range, 0.5 to 8 µg/ml) or elevated vancomycin MICs (≥4 µg/ml; range, ≤1 to ≥128 µg/ml); 24 showed elevated MICs to both antimicrobial agents. Both MRSA and methicillin-susceptible *S. aureus* (MSSA) were included in the study. Two vancomycin-resistant *S. aureus* isolates (vancomycin MICs of 1,024 and 64 µg/ml) from the Centers for Disease Control and Prevention (CDC; Atlanta, GA) were also included.

Of the 150 isolates, 62 were obtained from the culture collection of the CDC

and Project ICARE, 23 of which were reported previously as nonsusceptible to daptomycin (MIC range, 2 to 8 µg/ml) (16). Thirteen isolates were obtained from the Network on Antimicrobial Resistance in *Staphylococcus aureus* administered by Focus Technologies (Herndon, VA). Finally, 75 isolates of daptomycin-susceptible *S. aureus* were included from the culture collection of the Clinical Microbiology Institute (CMI; Wilsonville, OR).

The following quality control (QC) organisms were tested by each laboratory on each day of testing: *S. aureus* ATCC 25923 (disk diffusion only), *S. aureus* ATCC 43300 (disk diffusion only), *S. aureus* ATCC 29213 (broth microdilution and Etest), and *Enterococcus faecalis* ATCC 29212 (broth microdilution only) (24, 25). In addition, a known vancomycin-intermediate isolate of *S. aureus* (QC278) was included in each testing run at the CMI.

Test panels and media. Four sets of broth microdilution panels were prepared as described by the CLSI (24). CMI panels (prepared in house using CA-MHB [Difco lot 1110003]) contained the following serial twofold dilutions of antimicrobial agents: daptomycin, 0.12 to 128 µg/ml; oxacillin, 1 to 4 µg/ml; and vancomycin, 0.5 to 64 µg/ml. MIC panels prepared by the JMI Laboratories (North Liberty, Iowa) using CA-MHB from BBL had the same antimicrobial agent concentrations as the panels produced in house at the CMI. Panels prepared at TREK Diagnostics, Inc. (Cleveland, OH), contained serial twofold dilutions as follows: daptomycin, 0.03 to 32 µg/ml; oxacillin, 0.06 to 8 µg/ml; and vancomycin, 0.06 to 64 µg/ml. CDC MIC panels were prepared with CA-MHB from Difco (lot 2198184) contained the following dilution ranges: daptomycin, 0.5 to 16 µg/ml; oxacillin, 0.12 to 128 µg/ml; and vancomycin, 0.5 to 1,024 µg/ml. Daptomycin-containing microdilution wells in MIC panels prepared at the four study sites contained a final concentration of approximately 50 µg of calcium/ml. Additional antimicrobial agents were present on each of the MIC panels; however, the data from those antimicrobial agents were not analyzed for this study. For the Etest method, BBL Mueller-Hinton agar was used exclusively.

For disk diffusion tests, Mueller-Hinton agar media from three different manufacturers was used: BBL (lot # 4223273; Becton Dickinson, Franklin Lakes, NJ), Remel (lot 435212; Lenexa, KS), and Acumedia (lot 0402-123; Neogen Corp., Lexington, KY). The calcium concentrations of all broth and agar media were determined by using atomic absorption. The 150-mm plates were purchased from BBL, Remel, and Prepared Media Laboratories, respectively.

Broth microdilution. All 150 isolates were tested in duplicate at the CMI by broth microdilution on two separate days using CMI and JMI Laboratories panels. A subset of 34 isolates was tested in duplicate at the CDC on two separate days using CDC in-house panels and TREK panels. All sites performed broth microdilution in accordance with CLSI guidelines (24).

Etest. All 150 isolates were tested in duplicate at the CMI by the Etest method on two separate days using prepared agar media from BBL. At the CDC, the same subset of 34 isolates tested by broth microdilution was tested in duplicate by the Etest method on two separate days using prepared agar media from the same lot of BBL dehydrated base media as that used by the CMI. Daptomycin Etest strips with calcium supplementation were obtained from the manufacturer (AB Biodisk, Solna, Sweden) by both the CMI and the CDC. Etest procedures were performed according to manufacturer's guidelines. Etest MICs were rounded up to the next higher log₂ dilution corresponding to broth microdilution MICs for the purposes of comparison and analysis.

Disk diffusion. The CMI performed disk diffusion tests on the complete set of 150 isolates in triplicate on two separate days using media from three manufacturers (BBL, Remel, and Acumedia) and 30-µg daptomycin disks from two manufacturers (BBL and Oxoid [Remel]). The CDC performed disk diffusion tests on the subset of 34 isolates, which were also tested by broth microdilution and the Etest. Disk diffusion was performed in duplicate at the CDC using BBL media with 30-µg daptomycin disks obtained from BBL. The BBL dehydrated media and BBL disk lots used by the CDC were the same as those used by the CMI. Disk diffusion testing was performed in accordance with CLSI guidelines (25).

MBCs. Minimum bactericidal concentrations (MBCs) for daptomycin and vancomycin were determined on the complete set of 150 isolates at the CMI according to methods outlined by the CLSI (23) using Mueller-Hinton broth (BBL). The MBC was defined as the lowest concentration of the antimicrobial agent that produced a ≥99.9% (e.g., ≥3 log₁₀) drop in CFU/ml compared to the starting inoculum. The ratio of MBC to MIC was determined for each isolate.

Error rates. Since there is no intermediate interpretive category defined for daptomycin, all categorical errors are either very major errors (false susceptibility, where nonsusceptible values are equated with resistance) or major errors (false nonsusceptibility).

TABLE 1. Cumulative percent of *Staphylococcus aureus* inhibited or killed by daptomycin

MIC ($\mu\text{g/ml}$)	Daptomycin MIC								Daptomycin MBC (CMI)	
	Day 1 CMI panels		Day 2 CMI panels		Day 1 JMI panels ^a		Day 2 JMI panels ^a		MBC frequency	Cumulative % killed
	MIC frequency	Cumulative % inhibited	MIC frequency	Cumulative % inhibited	MIC frequency	Cumulative % inhibited	MIC frequency	Cumulative % inhibited		
0.06										
0.12										
0.25			2	1	28	19	27	19	1	1
0.5	1	53	72	49	65	64	61	61	38	26
1	34	76	38	75	36	89	37	87	56	63
2	25	93	28	93	11	97	12	95	32	85
4	10	99	9	99	5	100	7	100	15	95
8	1	100	1	100					8	100
16										
32										
64										
≥ 128										
Total	150	100	150	100	145	100	144	100	150	100

^a Several MIC panels were not readable.

RESULTS

Characterization of study isolates and comparison of broth microdilution results. Tables 1 and 2 show the cumulative percentage of the 150 *S. aureus* isolates selected for the present study that were either inhibited (MIC) or killed (MBC) by daptomycin or vancomycin, respectively, using CMI and JMI Laboratories MIC panels. For daptomycin, the MIC and MBC ranges determined at CMI were both 0.25 to 8 $\mu\text{g/ml}$. The MIC at which 50% of the isolates are inhibited (MIC_{50}) and MIC_{90} values for daptomycin using the CMI panels were 0.5 to 1.0 $\mu\text{g/ml}$ (depending on the day of testing) and 2 $\mu\text{g/ml}$, respectively, whereas the MBC_{90} was 4 $\mu\text{g/ml}$. Similar MICs were obtained using the JMI Laboratories panels (Table 1). The MIC_{50} and MIC_{90} values for daptomycin for the subset of 34 isolates, which had a larger percentage of nonsusceptible isolates, tested at CDC and CMI using the CMI panels were 1.0

$\mu\text{g/ml}$ and 2 to 4 $\mu\text{g/ml}$, respectively (data not shown). TREK panels tested at the CDC gave comparable MIC_{50} and MIC_{90} results. For vancomycin (Table 2), the MIC and MBC ranges were 0.5 to ≥ 128 $\mu\text{g/ml}$ and 1 to ≥ 128 $\mu\text{g/ml}$, respectively. The vancomycin MIC_{50} and MIC_{90} values were 2 and 8 $\mu\text{g/ml}$ for the CMI panels and 1 $\mu\text{g/ml}$ and 4 to 8 $\mu\text{g/ml}$ for the JMI Laboratories panels. The MBC_{90} for vancomycin was 64 $\mu\text{g/ml}$ for the set of 150 isolates. Among these isolates, the vancomycin MICs were higher than usual for *S. aureus* isolates (typical vancomycin $\text{MIC}_{90} = 1$ to 2 $\mu\text{g/ml}$) (2, 12, 26, 32, 34). No significant differences ($P > 0.05$) were noted between the results from the two test sites when results were analyzed by the MIC panel used, the day of testing, the modal MIC, the MIC range, the MIC_{50} , or the MIC_{90} .

Atomic absorption assays were used to assess the calcium concentration of the daptomycin-containing wells for the

TABLE 2. Cumulative percent of *Staphylococcus aureus* inhibited or killed by vancomycin

MIC ($\mu\text{g/ml}$)	Vancomycin MIC								Vancomycin MBC (CMI)	
	Day 1 CMI panels		Day 2 CMI panels		Day 1 JMI panels ^a		Day 2 JMI panels ^a		MBC frequency	Cumulative % killed 0.016
	MIC frequency	Cumulative % inhibited	MIC frequency	Cumulative % inhibited	MIC frequency	Cumulative % inhibited	MIC frequency	Cumulative % inhibited		
0.06										
0.12										
0.25										
0.5					1	1	2	1		
1	70	47	67	45	78	54	74	51	65	43
2	25	63	33	67	15	65	19	64	26	61
4	34	86	30	87	36	90	31	85	24	77
8	19	99	18	99	13	99	18	97	10	83
16					2	100	2	99	3	85
32							1	99	4	88
64	1	99	1	99					6	92
≥ 128	1	100	1	100	1	100	1	100	12	100
Totals	150	100	150	100	146	100	148	100	150	100

^a Several MIC panels were not readable.




FIG. 1. (A) Comparison of daptomycin Ettest MIC results obtained for 150 isolates of *S. aureus* tested in duplicate at the CMI and MIC results generated by broth microdilution reference method ($n = 300$). (B) Comparison of Ettest and broth microdilution MIC results for 34 *S. aureus* isolates tested in duplicate at the CDC. One MIC test at the CDC was not readable ($n = 67$). The susceptible breakpoints for daptomycin are $\leq 1 \mu\text{g/ml}$ for MIC testing.

plates prepared at the CMI, JMI Laboratories, and the CDC. The calcium ion concentrations of the MIC panels prepared at the CMI and JMI Laboratories were all $50 \mu\text{g/ml}$, whereas the CDC MIC panels had slightly lower calcium concentrations (range, 41 to $42 \mu\text{g/ml}$). The calcium concentrations of panels prepared at TREK were not available for testing, but all daptomycin quality control results for these panels were all within the acceptable ranges (4).

Ettest evaluation. There was good agreement among the day-to-day and institution-to-institution daptomycin MICs obtained with the Ettest method and those obtained by broth microdilution for the full set of 150 isolates tested in duplicate at the CMI (correlation coefficient [r] = 0.86; Fig. 1A) and the subset of 34 isolates tested in duplicate at the CDC ($r = 0.88$; Fig. 1B) and the CMI. The comparisons at lower MICs were limited since the CDC MIC panels did not evaluate daptomycin concentrations of $<0.5 \mu\text{g/ml}$. Testing performed at the CMI yielded daptomycin Ettest MIC_{50} and MIC_{90} values corresponding to those obtained by broth microdilution (i.e., $\text{MIC}_{50} = 1 \mu\text{g/ml}$; $\text{MIC}_{90} = 2 \mu\text{g/ml}$). At the CMI, 94.7% of the Ettest MICs were within $\pm 1 \log_2$ dilution of the broth microdilution values, although the Ettest MICs tended to be

lower. For example, 35.3% of the MICs were 1 \log_2 dilution lower, and 5.0% were 2 or 3 \log_2 dilutions lower. At the CDC, among the subsets of broth microdilution MICs of $\geq 1 \mu\text{g/ml}$ (i.e., on-scale values), 22 of 40 (55%) of the Ettest values were 1 \log_2 dilution higher than those observed with broth microdilution; none were lower.

Using the CMI data set ($n = 300$), 10 of 74 isolates reported as nonsusceptible by broth microdilution were reported as susceptible by Ettest for a very major error rate of 13.5%, and 9 of 226 isolates reported as susceptible based on broth microdilution isolates were reported as nonsusceptible by the Ettest for a major error rate of 4.0%. On the other hand, CDC Ettest results (which examined a set of isolates that was biased toward non-daptomycin-susceptible organisms) produced a major error rate of 35.9% but no very major errors were observed. A review of the quality control data from the CMI and CDC showed that all quality control results were within the ranges defined by CLSI. There was no demonstrable trend toward higher or lower MICs in either the CMI or the CDC data set.

Disk diffusion results. There was a high level of agreement between the zone diameters produced by BBL and Oxoid disks for the 150 study isolates tested at the CMI; 99.3% of the zone diameter values were within a $\pm 3\text{-mm}$ range (data not shown). There was also $>99\%$ agreement among the zone diameters observed on BBL, Remel, and Acumedia Mueller-Hinton agar (data not shown), demonstrating the overall reproducibility of the method. The calcium ion concentrations of the Mueller-Hinton agar lots used for disk diffusion ranged from 22 to $26 \mu\text{g/ml}$, which is considered acceptable for the daptomycin Ettest method (Ettest package insert) and is typical of BBL lots of Mueller-Hinton agar (data not shown).

Since there is no intermediate MIC range for daptomycin, all of the categorical errors observed in the present study were defined as very major errors (nonsusceptible values were equated with resistance). The very major error rate obtained at the CMI for daptomycin when comparing the categorical interpretation results for broth microdilution (using CMI panels) and disk diffusion was 24% for the set of 150 isolates. A scattergram of the CMI data showing the comparison of disk diffusion zone diameters to broth microdilution MICs is presented in Fig. 2. Additional tests comparing broth microdilution MICs and disk diffusion zones performed at CMI using a variety of media (BBL, Remel, and Acumedia) and disks (BBL and Oxoid) yielded very major rates ranging from 24 to 25%. Comparisons of the daptomycin MIC interpretations using JMI Laboratories MIC panels versus the interpretations for disk diffusion (BBL media and BBL disks), yielded a very major error rate of only 13%, since the MICs tended to be 1 \log_2 dilution lower but with essentially the same MIC_{50} and MIC_{90} values.

DISCUSSION

Interpretive criteria for daptomycin testing for both broth microdilution and disk diffusion testing were approved by the FDA in 2004 and published by the CLSI in 2005 (4). Previous studies indicated that isolates of *S. aureus* for which the daptomycin MICs were in the nonsusceptible range (i.e., MICs of $>1 \mu\text{g/ml}$) were appearing in the United States (16). Preliminary

This may be a source of variability that deserves additional study.

The results of disk diffusion testing were disappointing. Disk diffusion did not consistently identify isolates of *S. aureus* for which the daptomycin MICs were $>1 \mu\text{g/ml}$, even though the calcium concentrations of the agar used were $>20 \mu\text{g/ml}$ (12). Based in part on these data, the daptomycin disk test was withdrawn from the market in early 2005. However, using the Etest results as a model, it may be possible in the future to incorporate calcium into the daptomycin disk, much like glucose-6-phosphate has been incorporated in fosfomycin disks, to allow accurate disk diffusion testing (4). Until such disks can be manufactured and evaluated, clinical laboratories will have to use the broth microdilution reference method, the Etest, or the JustOne method (TREK) (19) or an alternate MIC method to assess the susceptibility of *S. aureus* isolates to daptomycin. Daptomycin testing using several automated susceptibility testing methods has been cleared recently by the U.S. FDA (R. Rennie, C. Brosnikoff, S. Shokoples, L. Turnbull, S. Mirrett, L. B. Reller, P. C. Iwen, R. K. Noel, M. Bacsafra, S. Connell, J. Johnston, and B. Zimmer, 15th Eur. Cong. Clin. Microbiol. Infect. Dis., abstr. P-1883, 2005; S. Messina-Powell, D. Pyse, K. Englehard, J. Moore, J. Slaughter, R. Griffith, A. Doan, and M. Ullery, Abstr. 105th Gen. Meet. Am. Soc. Microbiol. 2005, abstr. C-005, 2005), although the panels are not yet widely available.

Finally, the vancomycin MIC₅₀ and MIC₉₀ values of the non-daptomycin-susceptible isolates used in the present study were clearly above the values normally observed for *S. aureus* (2, 12, 26, 32, 34). In a previous report (16), we suggested the possible linkage of reduced susceptibility to vancomycin and nonsusceptibility of organisms to daptomycin. However, not all *S. aureus* isolates with reduced susceptibility to vancomycin showed a similar decrease in susceptibility to daptomycin. While 24 of the 150 study isolates showed decreased susceptibility to both drugs, 7 showed decreased susceptibility to vancomycin only, and 1 showed decreased susceptibility to daptomycin only. The mechanism of the purported linkage between reduced susceptibility to both drugs is unclear at this time. However, recent studies suggest that the thickened cell walls (5) characteristic of *S. aureus* strains with reduced susceptibility to vancomycin, the metabolic changes that accompany the formation of thickened cell walls (29), and mutations in the *mprF* and *ycyG* loci (11) may play a role in reduced susceptibility to daptomycin. Thus, clinical microbiologists and infectious disease clinicians should be aware that isolates of *S. aureus* that show reduced susceptibility to vancomycin may demonstrate reduced susceptibility to daptomycin as well.

ACKNOWLEDGMENTS

The findings and conclusions presented here are those of the authors and do not necessarily represent the views of the funding agency. The use of trade names in this study is for identification purposes only and does not constitute endorsement by the Public Health Service or the U.S. Department of Health and Human Services.

We thank David Lonsway and Jana Swenson for helpful discussions.

This study was supported by Cubist Pharmaceuticals, Inc. Phase 5 of Project ICARE is supported in part by unrestricted grants to the Rollins School of Public Health of Emory University by Astra-Zeneca Pharmaceuticals, Wilmington, DE; bioMérieux, Inc., Durham, NC; Elan Pharmaceuticals, San Diego, CA; and Pfizer Inc., New York, NY.

REFERENCES

- Arbeit, R. D., D. Maki, F. P. Tally, E. Campanaro, B. I. Eisenstein, and the Daptomycin 98-01 and 99-01 Investigations. 2004. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. *Clin. Infect. Dis.* **38**:1673-1681.
- Barry, A. L., P. C. Fuchs, and S. D. Brown. 2001. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. *Antimicrob. Agents Chemother.* **45**:1919-1922.
- Chambers, H. 2001. The changing epidemiology of *Staphylococcus aureus*? *Emerg. Infect. Dis.* **7**:178-182.
- Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing; CLSI approved standard M100-S16. Clinical and Laboratory Standards Institute, Wayne, Pa.
- Cui, L., E. Tominaga, H.-M. Neoh, and K. Hiramatsu. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **50**:1079-1082.
- Cunha, B. A. 2005. Methicillin-resistant *Staphylococcus aureus*: clinical manifestations and antimicrobial therapy. *Clin. Microbiol. Infect.* **11**:33-42.
- Deresinski, S. 2005. Methicillin-resistant *Staphylococcus aureus*: an evolutionary, epidemiological, and therapeutic odyssey. *Clin. Infect. Dis.* **40**:526-573.
- Eliopoulos, G. M. 2003. Quinupristin-dalfopristin and linezolid: evidence and opinion. *Clin. Infect. Dis.* **36**:473-481.
- Fluit, A. C., F. Schmitz, J. Verhoef, and D. Milatovic. 2004. In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants. *Antimicrob. Agents Chemother.* **48**:1007-1011.
- Fridkin, S. K. 2001. Vancomycin-intermediate and -resistant *Staphylococcus aureus*: what the infectious disease specialist needs to know. *Clin. Infect. Dis.* **32**:108-115.
- Friedman, L., J. D. Alder, and J. A. Silverman. 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **50**:2137-2145.
- Fuchs, P. C., A. L. Barry, and S. D. Brown. 2000. Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. *Diagn. Microbiol. Infect. Dis.* **38**:51-58.
- Fuchs, P. C., A. L. Barry, and S. D. Brown. 2001. Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media. *J. Antimicrob. Chemother.* **48**:557-561.
- Hayden, M. K., K. Rezai, R. A. Hayes, K. Lolans, J. P. Quinn, and R. A. Weinstein. 2005. Development of daptomycin resistance in vitro in methicillin-resistant *Staphylococcus aureus*. *J. Clin. Microbiol.* **43**:5285-5287.
- Hsueh, P., W. H. Chen, L. J. Teng, and K. T. Luh. 2005. Nosocomial infections due to methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. *Int. J. Antimicrob. Agents* **26**:43-49.
- Jevitt, L. A., A. J. Smith, P. P. Williams, P. M. Raney, J. E. McGowan, Jr., and F. C. Tenover. 2003. In vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin against a challenge panel of staphylococci and enterococci, including vancomycin-intermediate *Staphylococcus aureus* and vancomycin-resistant *Enterococcus faecium*. *Microb. Drug Resist.* **9**:298-306.
- Johnson, A. P., S. Mushtaq, M. Warner, and D. M. Livermore. 2004. Calcium-supplemented daptomycin Etest strips for susceptibility testing on Iso-Sensitest agar. *J. Antimicrob. Chemother.* **53**:860-862.
- Johnson, A. P., S. Mushtaq, M. Warner, and D. M. Livermore. 2004. Activity of daptomycin against multi-resistant gram-positive bacteria including enterococci and *Staphylococcus aureus* resistant to linezolid. *Int. J. Antimicrob. Agents* **24**:315-319.
- Jorgensen, J. H., and S. A. Crawford. 2006. Assessment of two commercial susceptibility test methods for determinant of daptomycin MICs. *J. Clin. Microbiol.* **44**:2126-2129.
- Lipsky, B. A., and U. Stoutenburgh. 2005. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. *J. Antimicrob. Chemother.* **55**:240-245.
- Mangili, A., I. Bica, D. R. Snyderman, and D. H. Hamer. 2005. Daptomycin-resistant, methicillin-resistant *Staphylococcus aureus* bacteremia. *Clin. Infect. Dis.* **40**:1058-1060.
- Munoz-Price, L. S., K. Lolans, and J. P. Quinn. 2005. Emergence of resistance to daptomycin during treatment of vancomycin-resistant *Enterococcus faecalis* infection. *Clin. Infect. Dis.* **41**:565-566.
- National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agent. Approved guideline M26-A, vol. 19, no. 18. National Committee for Clinical Laboratory Standards, Wayne, Pa.
- National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
- National Committee for Clinical Laboratory Standards. 2003. Performance

- standards for antimicrobial disk susceptibility tests. Approved standard M2–A8. National Committee for Clinical Laboratory Standards, Wayne, Pa.
26. Rybak, M. J., E. Hershberger, T. Moldovan, and R. G. Grucz. 2000. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. *Antimicrob. Agents Chemother.* **44**:1062–1066.
 27. Sabol, K., J. E. Patterson, J. S. Lewis II, A. Owens, J. Cadena, and J. H. Jorgensen. 2005. Emergence of daptomycin resistance in *Enterococcus faecium* during daptomycin therapy. *Antimicrob. Agents Chemother.* **49**:1664–1665.
 28. Saffdar, N., D. Andes, and W. A. Craig. 2004. In vivo pharmacodynamic activity of daptomycin. *Antimicrob. Agents Chemother.* **48**:63–68.
 29. Sakoulas, G., J. Alder, C. Thauvin-Eliopoulos, R. C. Moellering, Jr., and G. Eliopoulos. 2006. Induction of daptomycin heterogeneous susceptibility in *Staphylococcus aureus* by exposure to vancomycin. *Antimicrob. Agents Chemother.* **50**:1581–1585.
 30. Silverman, J. A., N. Oliver, T. Andrew, and T. Li. 2001. Resistance studies with daptomycin. *Antimicrob. Agents Chemother.* **45**:1799–1802.
 31. Smith, P. F., B. M. Booker, A. B. Ogunde, and P. Kelchin. 2005. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against gram-positive bacterial isolates from a large cancer center. *Diagn. Microbiol. Infect. Dis.* **52**:255–259.
 32. Snyderman, D. R., N. V. Jacobus, L. A. McDermott, J. R. Lonks, and J. M. Boyce. 2000. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. *Antimicrob. Agents Chemother.* **44**:3447–3450.
 33. Steenbergen, J. N., J. Alder, G. M. Thorne, and F. P. Tally. 2005. Daptomycin: a lipopeptide antibiotic for the treatment of serious gram-positive infections. *J. Antimicrob. Chemother.* **55**:283–288.
 34. Streit, J. M., R. N. Jones, and H. S. Sader. 2004. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical gram-positive organisms. *J. Antimicrob. Chemother.* **53**:669–674.
 35. Tenover, F. C., L. M. Weigel, P. C. Appelbaum, L. K. McDougal, J. Chaitram, S. McAllister, N. Clark, G. Killgore, C. M. O'Hara, L. Jevitt, J. B. Patel, and B. Bozdogan. 2004. Characterization of a vancomycin-resistant clinical isolate of *Staphylococcus aureus* from Pennsylvania. *Antimicrob. Agents Chemother.* **48**:275–280.
 36. Wise, R., J. M. Andrews, and J. P. Ashby. 2001. Activity of daptomycin against gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. *J. Antimicrob. Chemother.* **48**:563–567.